FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/15/2025
Back to search
Official data from USPTO
N NUAGE THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
04/03/2026
Trademark type
Combined
Nice classes
1, 5, 40, 42
Filing date
11/25/2022
Registration date
07/30/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/30/2024
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
ES
Examiner
BHANOT, KAPIL KUMAR
Law office
L80
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the wording NUAGE THERAPEUTICS in a stylized font with the letter "N" within a circular border to the left.
Holders and representatives
Holders
Nuage Therapeutics, S.L.
Representatives
Lawrence Apolzon Fross Zelnick Lehrman & Zissu, P.C.
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for use in product development in the fields of sciencescientific research and for laboratory use; in vitro analytical and diagnostic reagents for scientific use
Class 5
Pharmaceutical preparations for targeting of disordered proteins; chemicalanalytical and diagnostic reagents for in vitro medical or veterinary use; chemical reagents for medical use; chemical reagents for use in medical or veterinary diagnostics; pharmaceutical preparations for use in the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of ophthalmic diseases and conditions and for the treatment of inflammation and inflammatory conditions and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical products for the prevention and treatment of immune-relatedneurological and neurodegenerative diseases
Class 40
Custom manufacture of cell lines for use in the manufacture of biopharmaceutical products; custom manufacture of proteins for third parties; custom manufacture of medicines; custom manufacture of biopharmaceuticals
Class 42
Scientificmedicalmedical industrial research and development services; medical clinical research studies; laboratory medical research; research and development of new drugs and medical clinical products; analysis of materials; chemical analysis; medical and scientific laboratory services; laboratory medical testing services; medical laboratory services; information and advisory services relating to the aforesaidincluding such services provided online from a computer network or via the internet; research and development services for pharmaceutical preparations and for the treatment of diseases and injuries; genetic engineering services; genetic research for scientific or medical purposes; scientific research and development; scientific research in the field of genetics; medical and pharmacological research services; research and development in the fields of biotechnologybiopharmaceuticalsgene therapies; medical and scientific researchnamely conducting clinical trials; research and development of pharmaceutical products; research and development of vaccines and medicines; stem cell research; research and development in the fields of microorganisms and cells; research in the field of gene therapies; advisory services relating to gene therapy research; biological researchclinical medical research and medical research; product development; biological product development services; consultancy relating to pharmaceutical research and development; providing scientific information in the field of medical disorders and their treatment; pharmaceutical research and development; scientific services relating to the isolation and cultivation of human tissues and cells; research related to molecular science; analysis in the field of molecular biology; research services relating to molecular sciences
Publications
History of USPTO decisions and trademark events.
22 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/27/2025
FIMP
FINAL DISPOSITION PROCESSED
01/27/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/30/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/30/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
07/30/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/14/2024
PUBO
PUBLISHED FOR OPPOSITION
05/14/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/24/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/28/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/27/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/27/2024
RFNT
REFUSAL PROCESSED BY IB
10/17/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/27/2023
RFRR
REFUSAL PROCESSED BY MPU
09/27/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/09/2023
CNRT
NON-FINAL ACTION WRITTEN
09/08/2023
DOCK
ASSIGNED TO EXAMINER
09/06/2023
MAFR
APPLICATION FILING RECEIPT MAILED
05/26/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/22/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/18/2023
Continuous trademark protection
Get notified about every new filing that threatens N NUAGE THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.